Tiffany Radke
Acute Care · Saint Paul, MNNPI 1730588823
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 88.8% of it on its own, with 2 other manufacturers making up the rest.
Across 6 payments — averaging $56.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$299
- Musculoskeletal Transplant Foundation Inc.$21
- Smith+Nephew$17
What the payments were for
- Food & beverage$336100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 4 | $299 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $21 |
| Smith+Nephew | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$138
How this compares
$336 in reported general payments places this provider in the 80th percentile of 51 acute care providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $28,082 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,321 |
| Mirtazapine | 66 | $2,384 |
| Gabapentin | 67 | $1,592 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 12 | $1,374 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $1,289 |
| Levothyroxine Sodium | 70 | $1,180 |
| Entacapone | 13 | $1,048 |
| Trazodone Hcl | 78 | $1,010 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $971 |
| Divalproex Sodium | 29 | $929 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $844 |
| Sertraline Hcl | 37 | $695 |
| Potassium Chloride | 49 | $641 |
| Buspirone Hcl | 59 | $624 |
Paid to pharmacies, not to this prescriber.
Other acute care in Saint Paul
- Nicole KalamitsiotisSaint Paul$2K
- Kathleen BorchertSaint Paul$686
- Jennifer MikkelsonSaint Paul$283
- Megan KipferSaint Paul$268
- Erin LeachSaint Paul$131
- Amy WetzelSaint Paul$79
- Amanda PetersonSaint Paul$52
- Amelia SoleiSaint Paul$21
- Jacob ForsytheMaple Grove$7K
- Laura AshbachMinneapolis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.